Alerta

IDENTIFICATION OF NOVEL SMALL-MOLECULE INHIBITORS OF SARS-CoV-2 BY CHEMICAL GENETICS

Resumen de: US2025325535A1

This invention provides a novel small-molecule allosteric protease inhibitor, 10-(4-methylphenyl)-7-phenyl-6,7,8,10-tetrahydro-5H-indeno1,2-bquinoline-9,11-dione, which exhibits the highest selectivity index (SI), and shows inhibition against several SARS-CoV-2 variants of concern (VOC) and multiple human coronaviruses including MERS-CoV, SARS-CoV, and HCoV-229E. Not only does it demonstrate antiviral potency against a wide spectrum of coronavirus strains and species, but it also shows drug synergism with nirmatrelvir, which could be used in combination therapy to not only treat coronavirus-caused infections and diseases, but also lower the risk of antiviral resistance.

Dual-Action Recombinant Vesicular Stomatitis Virus (RVSV)-Based Vaccine (DAV) Against COVID-19 and Influenza Viruses

Resumen de: US2025325648A1

Described herein is a replicative Vesicular stomatitis virus (rVSV) comprising: a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein; and a second Filoviridae glycoprotein comprising a SARS-CoV2 Spike protein peptide inserted into the second Filoviridae glycoprotein, or a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein and a non-functional but immunogenic SARS-CoV2 Spike protein. The Spike protein or Spike protein peptide can be derived from different CoV-2 variants. The rVSV can be used as a Dual Action vaccine for vaccinating individuals simultaneously against both influenza virus and SARS CoV2 virus.

ANTIGENIC POLYPEPTIDE AND USE THEREOF

Resumen de: US2025325652A1

Provided are an isolated polypeptide or an antigenic fragment thereof, an antibody binding to the isolated polypeptide or the antigenic fragment thereof, a composition including the isolated polypeptide or the antigenic fragment thereof, and an array including the isolated polypeptide or the antigenic fragment thereof. Further provided a method for detecting the presence of an antibody against SARS-COV-2 in a subject, a method for the prognosis of the subject infected with SARS-COV-2, a method for inducing an immune response against SARS-CoV-2 in a subject, and a method for preventing and/or treating a disease caused by SARS-COV-2 infection in a subject.

Recombinant/Fusion Polypeptides Comprising Mutated Angiotensin Converting Enzyme 2 (ACE2)

Resumen de: US2025327052A1

The invention relates to recombinant mutated angiotensin converting enzyme 2 (ACE2) comprising one or more amino acid substitutions at amino acid positions T27, F28, K31, H34, Y41 and Q42 which have improved binding affinity to SARS-CoV-1 and/or SARS-CoV-2. It also relates to combinatorial mutant ACE2 comprising T27Y/K31 H/H34A, T27YZ K31 H/H134V and T27Y/K31 Y/H134V and the use of said mutant ACE2 for treating and preventing coronavirus infection.

METHODS OF COLLECTING AND ANALYZING DUST SAMPLES FOR SURVEILLANCE OF VIRAL DISEASES

Resumen de: US2025327142A1

Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.

VIRAL PREPARATIONS AND METHODS FOR TREATING AND MODULATING MITOCHONDRIAL EFFECTS OF CORONAVIRUS INFECTIONS.

Resumen de: US2025327038A1

Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.

VIRAL PREPARATIONS AND METHODS FOR TREATING AND MODULATING MITOCHONDRIAL EFFECTS OF CORONAVIRUS INFECTIONS.

Resumen de: US2025327039A1

Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.

NOVEL MAIN PROTEASE INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF

Resumen de: US2025326715A1

The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).

SARS-COV-2 CAMELID-DERIVED NANOBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND COMPOSITION THEREOF AND USE THEREOF

Resumen de: WO2025218020A1

Provided are a SARS-CoV-2 camelid-derived nanobody or an antigen-binding fragment thereof, and a composition thereof and a use thereof. The nanobody has at least 95% homology to SEQ ID NO: 1. Mutation engineering of the multivalent nanobody obtained by screening and purifying provides a method for rapidly generating an efficient virus neutralizing agent, such that viral escape mutants can be effectively controlled.

A MULTI-ANTIGENIC RNA SARS-COV-2 VACCINE AND ASSOCIATED METHODS

Resumen de: AU2023395159A1

The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.

NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF

Resumen de: US2025319125A1

The present application discloses neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments thereof that are effective against several SARS-COV-2 variants. Pharmaceutical compositions comprising the antibodies or antigen-binding fragments thereof are also disclosed. The antibodies, antigen-binding fragments thereof, or pharmaceutical compositions described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-COV-2 infection and/or COVID-19.

CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM

Resumen de: AU2024253607A1

An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.

Treatment for Coronavirus infection and associated cytokine toxicity

Resumen de: AU2025234176A1

The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the 5 immune system in coronavirus disease or infection, such as those from SARS-CoV-2. ep h e p r e s e n t i n v e n t i o n r e l a t e s t o n o v e l m e t h o d s c o m p r i s i n g t h e a d m i n i s t r a t i o n o f e p p e n t o s a n p o l y s u l f a t e f o r t r e a t i n g o r p r e v e n t i n g c o r o n a v i r u s i n f e c t i o n a n d c y t o k i n e - a s s o c i a t e d t o x i c i t y , i n c l u d i n g c y t o k i n e t o x i c i t y r e s u l t i n g f r o m a b e r r a n t a c t i v a t i o n o f t h e i m m u n e s y s t e m i n c o r o n a v i r u s d i s e a s e o r i n f e c t i o n , s u c h a s t h o s e f r o m - o -

THERAPEUTICS DIRECTED AGAINST CORONAVIRUS

Resumen de: US2025319197A1

This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as SARS-COV-1, SARS-COV-2 or a variant thereof. It is contemplated that the polypeptide can be further linked to a compound, wherein the compound extends the serum half-life of the polypeptide.

PHEROMONICIN AGAINST SARS-COV-2 AND USE THEREOF

Resumen de: US2025319181A1

A pheromonicin against SARS-COV-2. Antibody mimetics, i.e., two 28-residues are designed for the first time by selecting the E protein and M protein of SARS-COV-2, which are relatively conserved and have low probability of mutation, as targets. Pharmacodynamic experiments performed using three SARS-COV-2 strains (the epidemic strain GD108, the South Africa strain SA and the India strain IND) respectively prove that fusion proteins obtained by linking the 28-residues to colicin can provide effective protective efficacy against pulmonary lesions induced by SARS-COV-2, and can be used as drugs for treating and preventing SARS-COV-2.

METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19

Resumen de: US2025319060A1

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

PIV5-BASED COVID-19 VACCINE

Resumen de: US2025319176A1

The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) protein for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

MULTISPECIFIC ANTIBODY

Resumen de: WO2025214462A1

A multispecific antibody or an antigen-binding molecule thereof, a homodimer thereof, a nucleic acid molecule encoding the multispecific antibody or the antigen-binding molecule thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a recombinant protein or immunoconjugate comprising the multispecific antibody or the antigen-binding molecule thereof, a use thereof in the preparation of a medicament for treating or preventing respiratory tract infections caused by viruses or in the preparation of a medicament for treating or preventing respiratory tract inflammation or dermatitis, and in a detection product. The multispecific antibody or the antigen-binding molecule thereof has excellent broad-spectrum neutralizing capability for coronaviruses and significant neutralizing capacity for coronavirus mutant strains, especially a variety of SARS-CoV-2 coronavirus mutant strains including Omicron subvariants BQ.1.1, XBB.1.5, XBB.1.16, EG.5, BA.2.86, and JN.1. The multispecific antibody or the antigen-binding molecule thereof can not only treat or prevent respiratory tract infection symptoms caused by viruses but also significantly relieve respiratory tract inflammation responses. The multispecific antibody or the antigen-binding molecule thereof has a good therapeutic effect on inflammatory diseases such as rhinitis, asthma, and dermatitis and has good clinical application prospects in the future.

METHOD OF TREATING AND PREVENTING VIRAL INFECTIONS

Resumen de: US2025318951A1

A method for treating viral infections caused by viruses whose survival time depends on temperature (e.g., cold viruses, flu viruses, COVID-19, etc.) is based on administrating to a subject an effective amount of thermal energy transferred from a hotter liquid product to the colder subject using a predetermined combination of the temperature of the liquid product, the duration of time of supplying the liquid product, and the amount of the liquid product. This method of treatment inactivates viruses in the upper respiratory tract and gastrointestinal tract of the subject and enhances the response of the immune system, thereby preventing complications and accelerating the recovery of the infected subject.

CHIMERIC ANTI-SARS-COV2 NUCLEOPROTEIN ANTIBODIES

Resumen de: US2025320278A1

Compositions and methods are disclosed for diagnosing, treating, and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus nucleoprotein or mutants thereof. In embodiments, the coronavirus is SARS-CoV-2

UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES

Resumen de: US2025320255A1

Self-adjuvanting vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Self-adjuvanting vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immunogen is glycosylated to allow for mucosal delivery. Self-adjuvanting vaccine compositions comprising multivalent carriers and related methods using the self-adjuvanting vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection. Pathogens for which this approach may be useful include, but are not limited to, influenza viruses, rhinoviruses, human immunodeficiency viruses (HIV), respiratory syncytial virus (RSV), coronaviruses, Babesia, Borrelia, Neisseria, and Chlamydia, and the related diseases thereof.

USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS

Resumen de: US2025319160A1

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

3-AZASTEROID COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO MITROCHONDRIAL FUNCTION

Resumen de: US2025320246A1

Compounds of formula (I):wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrome and myalgic encephalomyelitis (ME, chronic fatigue syndrome) or post viral syndrome, including chronic symptoms arising from infection with SARS-CoV2 (long COVID).

MONOCLONAL ANTIBODIES FOR THE TREATMENT OF VIRAL INFECTIONS

Resumen de: US2025320308A1

The present invention provides for monoclonal anti-IFITM2 and anti-IFITM3 antibodies or a fragment thereof, pharmaceutical compositions comprising said antibodies and its use in the treatment of viral infections, preferably of SARS-COV-2 infection in host human cells.

ANTIBODIES OR FRAGMENTS THEREOF FOR SARS-COV-2 AND VARIANTS THEREOF

Nº publicación: EP4630447A2 15/10/2025

Solicitante:

ABWIZ BIO INC [US]
Abwiz Bio, Inc

Resumen de: WO2024124241A2

This disclosure generally relates to humanized antibodies and their therapeutic use. More specifically, this disclosure is in the field of producing humanized antibodies that are optimized for biological and chemical features, including acitivies against SARS-CoV-2 variants, such as omicron variants.